Biosimilars are highly similar- but more affordable- successors to biologic drugs whose patents have expired. Unlike generics, biosimilars are not exact copies of originators because the manufacturing process of these large, complex molecules is too difficult to replicate precisely. For this reason, biosimilars require comprehensive evaluation to gain regulatory approval.